← 返回

通过靶向递送原位生成的抗原和钙离子载体实现抗原特异性 T 细胞激活以增强抗肿瘤免疫治疗

英文原题:Antigen-specific T cell activation through targeted delivery of in-situ generated antigen and calcium ionophore to enhance antitumor immunotherapy.

查看英文原题

Antigen-specific T cell activation through targeted delivery of in-situ generated antigen and calcium ionophore to enhance antitumor immunotherapy.

PubMed 2023/12/06(内容时间) J Control Release Q1 · IF 12.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

近年来,过继性T细胞疗法的进展通过激发持久的抗肿瘤反应,取得了令人瞩目的治疗效果。然而,由于多种因素,实现特异性T细胞激活仍然是一项挑战。一些癌细胞由于肿瘤特异性T细胞稀缺以及抗原加工或主要组织相容性复合体(MHC)呈递缺陷而逃避免疫T细胞识别。尤其被低估的是T细胞受体(TCR)表达减弱以及树突状细胞(DCs)与T细胞之间免疫突触(IS)形成受限所造成的影响,这会损害T细胞激活。为解决这些复杂问题,我们提出了一种开创性方法,其特点是部署一种凝胶植入物。该植入物可在原位建立抗原储库,有效靶向淋巴结中的DCs,并促进钙离子(Ca 2+)递送。该凝胶经过工程化设计,具有可控溶胀性、多孔弹性和回弹性,适合外科植入。其充足的包封能力可同时容纳光敏剂和纳米颗粒。在原位光热照射下,该凝胶可产生肿瘤特异性抗原。

此外,共载单磷酸酰脂质A(MPLA)和离子霉素的阳离子白蛋白纳米颗粒(cNPs)被释放,引导抗原前往肿瘤引流淋巴结以促进DCs成熟。这一精细过程促进IS形成,从而增强抗原特异性T细胞激活。

展开英文摘要原文

Recent advances in adoptive T-cell therapy have delivered impressive therapeutic outcomes by instigating enduring anti-tumor responses. Nonetheless, achieving specific T-cell activation remains a challenge due to several factors. Some cancer cells evade T-cell recognition due to the scarcity of tumor-specific T cells and deficiencies in antigen processing or major histocompatibility complex (MHC) presentation.

Notably underestimated is the impact of waning T-cell receptor (TCR) expression and the constrained formation of immune synapses (IS) between dendritic cells (DCs) and T cells, impairing T-cell activation. Addressing these complexities, we introduce a pioneering approach featuring the deployment of a gel implant.

This implant establishes an on-site antigen reservoir, efficiently targets DCs in lymph nodes, and facilitates calcium ion (Ca 2+ ) delivery. Engineered with controlled swelling, poroelasticity, and resilience, the gel is suitable for surgical implantation. Its ample encapsulation capacity accommodates both photosensitizers and nanoparticles. Upon in situ photothermal irradiation, the gel generates tumor-specific antigens.

Furthermore, cationic albumin nanoparticles (cNPs) co-loaded with monophosphoryl lipid A (MPLA) and ionomycin are released, guiding antigens to tumor-draining lymph nodes for DCs maturation. This meticulous process fosters the formation of IS thereby amplifying antigen-specific T-cell activation.

论文信息

作者
Chen X、Ouyang H、Zhang Y、Chen C、Nan S、Pu X、Gong T、Zhang ZR
第一作者单位
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.China
通讯作者单位
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China. Electronic address: yfu4@scu.edu.cn.China
文献类型
非美国政府资助研究
期刊
Journal of controlled release : official journal of the Controlled Release Society2024 Jan
原文标识
PubMed 38052255 · DOI 10.1016/j.jconrel.2023.12.002